Spoken Alpha
Elanco Animal Health Inc
Elanco Animal Health provides medicines, vaccines, and other products to prevent and treat disease in pets and farm animals. The company sells approximately 200 brands globally, including parasiticides, dermatology treatments, and vaccines for dogs and cats, and efficiency, disease prevention, and food safety products for cattle, poultry, swine, and sheep.
Elanco Animal Health Inc is a Healthcare company operating in Drug Manufacturers - Specialty & Generic with a $11.57B market cap.
Most recent reported earnings: Q3 FY2026 (Nov 5, 2026).
22 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-08-30.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for ELAN.
$ curl https://api.spokenalpha.com/v1/companies/ELANFAQ
Spoken Alpha indexes ELAN's earnings call transcripts at https://spokenalpha.com/companies/ELAN. Each call links to attributed speakers and parsed analyst Q&A. Elanco Animal Health Inc's own investor relations page is at https://investor.elanco.com/.
Elanco Animal Health Inc (ELAN) held its most recent earnings call on 2026-08-05, covering fiscal Q2 2026.
Elanco Animal Health Inc (ELAN) operates in the Healthcare sector (Drug Manufacturers - Specialty & Generic industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 2026-11-05 | — | $0.20 | — | — | — | — | EODHD |
| Q2 FY2026 | 2026-08-04 | $0.34 | $0.27 | +25.9% | $1.37B | — | — | EODHD |
| Q1 FY2026 | 2026-05-05 | $0.40 | $0.34 | +17.6% | $1.37B | — | — | EODHD |
| Q4 FY2025 | 2026-02-24 | $0.13 | $0.11 | +14.5% | $1.14B | — | — | EODHD |
| Q3 FY2025 | 2025-11-04 | $0.19 | $0.13 | +46.2% | $1.14B | — | — | EODHD |
| Q2 FY2025 | 2025-08-06 | $0.26 | $0.20 | +30.0% | $1.24B | — | — | EODHD |
| Q1 FY2025 | 2025-05-06 | $0.37 | $0.30 | +23.3% | $1.19B | — | — | EODHD |
| Q4 FY2024 | 2025-02-23 | $0.14 | $0.15 | -5.8% | $1.02B | — | — | EODHD |
| Q3 FY2024 | 2024-11-06 | $0.13 | $0.12 | +8.3% | $1.03B | — | — | EODHD |
| Q2 FY2024 | 2024-08-07 | $0.30 | $0.24 | +25.0% | $1.18B | — | — | EODHD |
| Q1 FY2024 | 2024-05-07 | $0.34 | $0.27 | +25.9% | $1.21B | — | — | EODHD |
| Q4 FY2023 | 2024-02-25 | $0.08 | $0.11 | -27.3% | $1.03B | — | — | EODHD |
| Q3 FY2023 | 2023-11-06 | $0.18 | $0.12 | +50.0% | $1.07B | — | — | EODHD |
| Q2 FY2023 | 2023-08-06 | $0.18 | $0.05 | +100.0% | $1.06B | — | — | EODHD |
| Q1 FY2023 | 2023-05-08 | $0.45 | $0.29 | +55.2% | $1.26B | — | — | EODHD |
| Q4 FY2022 | 2023-02-20 | $0.19 | $0.13 | +46.2% | $988.0M | — | — | EODHD |
| Q3 FY2022 | 2022-11-07 | $0.20 | $0.16 | +25.0% | $1.03B | — | — | EODHD |
| Q2 FY2022 | 2022-08-07 | $0.36 | $0.25 | +44.0% | $1.18B | — | — | EODHD |
| Q1 FY2022 | 2022-05-08 | $0.36 | $0.35 | +2.9% | $1.23B | — | — | EODHD |
| Q4 FY2021 | 2022-02-23 | $0.21 | $0.17 | +23.5% | $1.11B | — | — | EODHD |
Source: EODHD. ELAN reported actuals as published; sparse fields render as —.